Prime Medicine shares are trading higher after the company announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to PM359.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!